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LETTER TO THE EDITOR
Tumor Cell Content for
Selection of Molecular
Techniques for T790M
EGFR Mutation
Detection in Non-small
Cell Lung Cancer
To the Editor:
As recently published by Schuurbiers
et al.1 in the October 2010 issue of the
Journal of Thoracic Oncology, with
transesophageal and endobronchial ul-
trasound-guided fine needle cytologi-
cal aspirations, cytologic specimens
could be successfully used for routine
molecular analysis in non-small cell
lung cancer (NSCLC). In some cases,
cytologic samples could be more use-
ful than paired tumor tissue samples
depending on tumor cell count.
After an initial disease control, most
of the patients with an EGFR activating
mutation develop acquired resistance to
epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs), due to an
additional mutation in EGFR (exon 20,
T790M) in 50% of cases. Several new
agents are currently under clinical devel-
opment in purpose to overcome the differ-
ent mechanisms of resistance to EGFR-
TKIs and are based on the molecular
characterization of the tumor at the time of
progression depending on the sensitivity
of the molecular test.2
Using all the available NSCLC
samples for molecular testing could be
important in the perspective of routine
analysis. Besides bronchial biopsies, cy-
tological specimens could be used for
molecular analysis of NSCLC. Previous
studies related detection of EGFR muta-
tions in some other cytological samples,
mostly pleural fluid and fine needle as-
piration or cerebrospinal fluid. Bronchi-
oloalveolar lavage (BAL) could also be
successfully used for molecular analy-
sis. By direct sequencing, we detected a
resistance T790M EGFR mutation asso-
ciated with a sensitive L858R EGFR
mutation in the DNA extracted from a
BAL of a case of adenocarcinoma with
bronchioloalveolar carcinoma feature
(ADC-WBF) but not in the paired DNA
from bronchial biopsy which contained
5% of tumor cells.
Detection of mutation depends on
the sensitivity of the used molecular
methods which must be related to tu-
mor cell content of the analyzed tumor
sample. As we previously did for K-RAS
mutation diagnosis, we developed an
alternative more sensitive molecular
method for the diagnosis of the T790M
EGFR mutation using real-time peptide
nucleic acid (PNA)-mediated poly-
merase chain reaction clamping assay,
allowing the detection of the T790M
EGFR mutation in the bronchial biopsy,
and also confirmed the presence of this
mutation in the BAL of our patient (Fig-
ure 1).3 Such alternative molecular tech-
nique could be interesting to identify
one of the EGFR-TKI resistance
mechanisms at the time of progression
and also to detect mutant subclones
that may be present before exposure to
any drug. Such mutated T790M sub-
clones seem to be associated with a
reduced progression-free survival un-
der EGFR-TKIs treatment.
The choice of the sample for rou-
tine molecular analysis should depend
more on the percentage of tumor cells in
the available samples rather than on the
type of sample. Moreover technical de-
velopment of more sensitive molecular
techniques could be helpful in clinical
practice of poor tumor samples without
using microdissection. So, preanalytic
step with quantification of tumor cell
count is crucial for molecular analysis of
NSCLC samples to correctly choose the
molecular techniques and minimize the
risk of false-negative results.
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FIGURE 1. Real-time peptide nucleic acid (PNA)-mediated polymerase chain reac-
tion (PCR) clamping assay for EGFR T790M mutation detection. Delta-delta com-
puted tomography (CT) values (in ordered) of PNA-mediated PCR clamping are
calculated from 10 independent serially diluting DNA (1%, 10%, 100%) of H1975-
mutant cell line (EGFR T790M heterozygous mutation) into the DNA of HT29 wild-
type EGFR cell line. Box plots represented delta-delta CT values with gray boxes
(median and IC range [25–75]), bars (IC 5–95), and extreme values with no over-
lap value between the different cell line dilutions. Delta-delta CT values for bron-
chial biopsy (BB) containing 5% of tumor cells and paired bronchioloalveolar la-
vage (BAL) of a patient with adenocarcinoma with bronchioloalveolar carcinoma
feature (ADC-WBF) are indicated.
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Erratum
Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer: Erratum
In the article that appeared on page 1221 of the July issue, the authors omitted to mention that the composition of our multidisciplinary tumor board
(referred to in the section ‘Patients and Treatment’) also includes thoracic surgeons and pathologists.
In addition, although a previous paper reporting on the classification of CT findings after lung irradiation was cited, they did not acknowledge two original
references in this field, namely, (1) Ikezoe J, Takashima S, Morimoto S, et al. CT appearance of acute radiation-induced injury in the lung. AJR Am J
Roentgenol. 1988;150:765–770 and (2) Koenig TR, Munden RF, Erasmus JJ, et al. Radiation injury of the lung after three-dimensional conformal
radiation therapy. AJR Am J Roentgenol. 2002;178:1383–1388.
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